QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
QIAGEN has launched two new tools for customizing microbial analysis solutions: a first-of-its-kind Custom dPCR Microbial Assays design tool and QIAseq xHYB Custom Microbial Panels. The dPCR tool enables customized primer and probe design for bacterial, fungal, and viral targets, while the NGS panels allow comprehensive genome coverage for improved microbial detection. These additions complement QIAGEN's existing portfolio of over 700 digital PCR assays for microbial targets, accessible through the GeneGlobe platform. The new tools enhance capabilities in applications ranging from wastewater testing to food production and human pathogen analysis.
QIAGEN ha lanciato due nuovi strumenti per personalizzare le soluzioni di analisi microbica: un innovativo strumento di design per Assay Microbici Custom dPCR e i Pannelli Microbici Custom QIAseq xHYB. Lo strumento dPCR consente la progettazione personalizzata di primer e sonde per obiettivi batterici, fungini e virali, mentre i pannelli NGS offrono una copertura genomica completa per un miglior rilevamento microbico. Queste aggiunte completano il portafoglio esistente di oltre 700 assay di PCR digitale per obiettivi microbici di QIAGEN, accessibili tramite la piattaforma GeneGlobe. I nuovi strumenti potenziano le capacità in applicazioni che spaziano dai test delle acque reflue alla produzione alimentare e all'analisi dei patogeni umani.
QIAGEN ha lanzado dos nuevas herramientas para personalizar soluciones de análisis microbiano: una herramienta de diseño de Assays Microbianos Custom dPCR única en su tipo y Páneles Microbianos Custom QIAseq xHYB. La herramienta de dPCR permite el diseño personalizado de cebadores y sondas para objetivos bacterianos, fúngicos y virales, mientras que los paneles de NGS permiten una cobertura genómica completa para una mejor detección microbiana. Estas adiciones complementan el portafolio existente de más de 700 ensayos de PCR digital para objetivos microbianos de QIAGEN, accesibles a través de la plataforma GeneGlobe. Las nuevas herramientas mejoran las capacidades en aplicaciones que van desde el análisis de aguas residuales hasta la producción de alimentos y el análisis de patógenos humanos.
QIAGEN는 미생물 분석 솔루션을 맞춤화하기 위한 두 가지 새로운 도구를 출시했습니다: 독창적인 맞춤형 dPCR 미생물 어세이 디자인 도구와 QIAseq xHYB 맞춤형 미생물 패널입니다. dPCR 도구는 박테리아, 곰팡이 및 바이러스 표적에 대한 맞춤형 프라이머와 프로브 디자인을 가능하게 하며, NGS 패널은 향상된 미생물 탐지를 위해 전체 유전 정보를 포괄적으로 제공합니다. 이러한 추가 도구는 GeneGlobe 플랫폼을 통해 접근 가능한 700개 이상의 디지털 PCR 어세이를 포함하는 QIAGEN의 기존 포트폴리오를 보완합니다. 새로운 도구는 폐수 검사부터 식품 생산 및 인체 병원체 분석에 이르는 다양한 응용 프로그램에서의 능력을 향상시킵니다.
QIAGEN a lancé deux nouveaux outils pour personnaliser les solutions d'analyse microbienne : un premier outil de conception d'Assays Microbiens Custom dPCR et des Panneaux Microbiens Custom QIAseq xHYB. L'outil dPCR permet une conception personnalisée des amorces et des sondes pour des cibles bactériennes, fongiques et virales, tandis que les panneaux NGS offrent une couverture complète du génome pour une détection microbienne améliorée. Ces ajouts viennent compléter le portefeuille existant de plus de 700 assays PCR numériques pour des cibles microbiens de QIAGEN, accessibles via la plateforme GeneGlobe. Les nouveaux outils renforcent les capacités dans des applications allant de l'analyse des eaux usées à la production alimentaire et à l'analyse des pathogènes humains.
QIAGEN hat zwei neue Werkzeuge zur Anpassung von mikrobiellen Analyseverfahren auf den Markt gebracht: ein maßgeschneidertes dPCR-Mikrobenassay Designwerkzeug und QIAseq xHYB Custom Mikrobellen. Das dPCR-Werkzeug ermöglicht eine maßgeschneiderte Primer- und Sondenentwicklung für bakterielle, pilzliche und virale Ziele, während die NGS-Panels eine umfassende Genomabdeckung für eine verbesserte mikrobielle Erkennung bieten. Diese Ergänzungen erweitern das bestehende Portfolio von über 700 digitalen PCR-Assays für mikrobielle Ziele von QIAGEN, die über die GeneGlobe-Plattform zugänglich sind. Die neuen Werkzeuge verbessern die Fähigkeiten in Anwendungen, die von Abwasseranalysen über die Lebensmittelproduktion bis hin zur Analyse menschlicher Pathogene reichen.
- First-to-market customizable digital PCR assay design tool for microbial applications
- Expands product portfolio with advanced NGS panels offering improved genome coverage
- Builds upon existing portfolio of 700+ digital PCR assays for microbial targets
- None.
Insights
The launch of customizable digital PCR assay design tools and NGS panels represents a significant advancement in microbial analysis capabilities. The first-of-its-kind Custom Assay Design Tool addresses critical market needs in pathogen detection and research, while the QIAseq xHYB Custom Microbial Panels overcome traditional coverage limitations in genome sequencing.
These tools enhance QIAGEN's competitive position in the molecular diagnostics market by offering superior flexibility and accuracy in detecting bacterial, fungal and viral targets. The technology's ability to measure rare targets in low-biomass samples with high PCR inhibitors, without requiring standard curves, provides a distinct advantage in applications ranging from wastewater testing to food safety monitoring.
While this product launch strengthens QIAGEN's research tools portfolio, its immediate financial impact may be moderate as market adoption and revenue generation will take time to materialize. The expansion adds to their existing base of 700+ digital PCR assays, potentially driving incremental growth in their Life Sciences segment.
QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custom Assay Design Tool for Microbial dPCR Assays offers unparalleled flexibility in digital PCR analysis of bacterial, fungal and viral targets // QIAseq xHYB Custom Microbial Panels enable high-resolution sequencing by covering multiple whole genomes, overcoming coverage gaps common in standard panels
Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial, fungal and viral targets.
These new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system. They also build on more than 700 digital PCR assays that are currently available for microbial targets through the GeneGlobe platform at https://geneglobe.qiagen.com.
The new products make nanoplate digital PCR (dPCR) suitable for even more microbial targets in applications ranging from wastewater testing to food production to analysis of human pathogens. With nanoplate dPCR, rare targets in low-biomass samples with high levels of PCR inhibitors can be measured without a standard curve and with high accuracy and precision.
“The demands for microbial detection, tracking and scientific research can be extremely specialized. Reliable and accurate tools that can be customized give scientists the flexibility they need to outpace pathogens and accelerate the tempo of discovery,” said Nitin Sood, Senior Vice President and head of QIAGEN’s Life Sciences Business Area. “With the launch of our design tool for Custom dPCR Microbial Assays and the new QIAseq xHXB panels, we are addressing the demands of our customers. QIAGEN will continue to expand our offering of accurate, reliable and easy-to-use solutions.”
The new tools are:
- Design tool for Custom dPCR Microbial Assays – The first-of-its-kind custom assay design tool enables users to design primers and probes for their specific microbial targets of interest and is tailored specifically for bacterial, fungal and viral targets.
The design tool software is powered by a sophisticated and thoroughly tested algorithm developed specifically for microbial applications. Researchers can benefit from a user-friendly and intuitive tool that helps them quickly obtain custom assays with optimal sensitivity, specificity and accurate off-target prediction.
- QIAseq xHYB Custom Microbial Panels – Customers can completely design their own NGS panels, overcoming limitations of panels offered by other vendors, which are designed against a few genomes of a given target and thereby often cause large gaps in coverage. The QIAseq xHYB Custom Microbial Panels advanced algorithm enables researchers to design their assays against many whole genomes at once, allowing them to achieve the highest possible resolution in applications such as microbial detection.
QIAGEN continues to expand its portfolio dPCR assays, supporting laboratories to increase their detection capabilities and improve their results. In September, the company added over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications. These newly launched cancer and microbial assays meet the level of quality, multiplexing capabilities, customization, precision and sensitivity associated with all QIAcuity products.
Customizable digital PCR assays and the customizable panels and assays are now available on QIAGEN’s GeneGlobe web portal (https://geneglobe.qiagen.com), which integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs and pathways.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
FAQ
What new products did QIAGEN (QGEN) launch for microbial analysis in November 2023?
How many digital PCR assays does QIAGEN (QGEN) currently offer for microbial targets?
What applications are supported by QIAGEN's (QGEN) new microbial analysis tools?
